Statera Biopharma, Inc. (CBLI) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Cash flows from operating activities:
Net loss	-101.9	-12.1	-2.7	-3.7	-9.8	-2.6	-13.0	0.0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	0.0	0.0			0.0	0.1	0.1	0.2
Amortization expense	0.2
Noncash interest expense	0.0
Stock based compensation	6.1	2.7				0.0	0.1	0.5
Noncash lease expense	0.0	0.0
Changes in operating assets and liabilities:
Other current assets	0.9	-0.3				0.2	-0.3	0.0
Accounts receivable	-0.4				-0.1	0.3	-0.4	0.6
Short term investments
Prepaid expenses	-1.0
Contract asset	-0.1
Contract liability	-0.1
Accounts payable and accrued expenses	1.0	0.3	0.2	-0.3	-1.0	0.3	-0.6	0.7
Net cash used in operating activities	-28.2	-5.1	-2.7	-4.6	-6.6	-5.0	-12.1	-14.5

Cash flows from investing activities:
Purchase of property and equipment	-0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash acquired, acquisition
Net cash provided by (used in) investing activities	13.5	0.0	0.2	4.0	3.9	5.7	-10.3	-1.8

Cash flows from financing activities:
Proceeds from issuance of common	7.3						27.2	9.7
Payment of debt issuance costs	-0.3
Stock issuances due	0.3
Repayments on notes payable	-0.9						-2.7	-4.2
Net cash provided by (used in) financing activities	21.0	5.7		0.1		0.5	24.9	10.6
Effect of exchange rate change on cash and equivalents	0.0
Increase (decrease) in cash and cash equivalents	6.3	0.6

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	1.3						0.5	0.5
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Right of use asset exchanged for lease liability	0.2
Debt principal converted